MCID: BRN035
MIFTS: 51

Brain Stem Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Stem Glioma

MalaCards integrated aliases for Brain Stem Glioma:

Name: Brain Stem Glioma 12 15 17
Brainstem Neuroglial Tumor 12
Glioma of Brainstem 72
Brainstem Glioma 6

Classifications:



External Ids:

Disease Ontology 12 DOID:4202
NCIt 50 C8501
UMLS 72 C0677865

Summaries for Brain Stem Glioma

Disease Ontology : 12 A brain stem cancer that is characterized by mass lesion of the brainstem, associated cranial nerve nuclei and long tracts, has material basis in abnormally proliferating cells, derives from glial cells.

MalaCards based summary : Brain Stem Glioma, also known as brainstem neuroglial tumor, is related to grade iii astrocytoma and glioblastoma multiforme. An important gene associated with Brain Stem Glioma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Levoleucovorin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 75 A brainstem glioma is a cancerous glioma tumor in the brainstem. Around 75% are diagnosed in children... more...

Related Diseases for Brain Stem Glioma

Diseases in the Brain Stem Glioma family:

Adult Brain Stem Glioma

Diseases related to Brain Stem Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 grade iii astrocytoma 30.9 TP53 IDH2 EGFR BSG
2 glioblastoma multiforme 30.8 TP53 PIK3CA PDGFB IDH1 EGFR
3 gliomatosis cerebri 30.7 TP53 IDH1 EGFR
4 glioma 30.6 TP53 PIK3CA PDGFB IDH2 IDH1 FGFR1
5 fibrillary astrocytoma 30.6 TP53 IDH2 IDH1
6 supratentorial cancer 30.4 TP53 IDH2 IDH1 EGFR
7 gliosarcoma 30.4 TP53 IDH1 FGFR1 EGFR
8 oligodendroglioma 30.4 TP53 PDGFB IDH2 IDH1 EGFR
9 brain stem cancer 30.2 TP53 TMPRSS11D PPM1D PDGFB BSG
10 glioblastoma 29.9 TP53 PIK3CA PDGFB IDH2 IDH1 FGFR1
11 brain cancer 29.5 TP53 PIK3CA PDGFB IDH2 IDH1 EGFR
12 medulloblastoma 29.4 TP53 PPM1D PIK3CA PDGFB IDH1 FGFR1
13 childhood brain stem glioma 12.8
14 adult brain stem glioma 12.6
15 diffuse intrinsic pontine glioma 11.7
16 brain stem astrocytic neoplasm 11.3
17 brain stem ependymoma 11.3
18 glial tumor 10.8
19 brain ependymoma 10.8 TP53 EGFR
20 interval angle-closure glaucoma 10.7 IDH2 IDH1
21 nevus of ota 10.7 TP53 BRAF
22 adult hepatocellular carcinoma 10.7 TP53 PIK3CA
23 irinotecan toxicity 10.7 UGT1A1 UGT1A EGFR
24 rare adenocarcinoma of the breast 10.7 TP53 PIK3CA
25 cerebellar astrocytoma 10.7 TP53 IDH1
26 enchondroma 10.7 IDH2 IDH1
27 malignant spiradenoma 10.7 TP53 PIK3CA
28 breast squamous cell carcinoma 10.7 TP53 PIK3CA EGFR
29 brain glioma 10.6 TP53 IDH1 EGFR
30 penile cancer 10.6 TP53 PIK3CA EGFR
31 adenosquamous carcinoma 10.6 TP53 PIK3CA EGFR
32 intracranial chondrosarcoma 10.6 TP53 IDH2 IDH1
33 estrogen-receptor positive breast cancer 10.6 TP53 PIK3CA EGFR
34 pleomorphic xanthoastrocytoma 10.6 TP53 IDH1 BRAF
35 adult oligodendroglioma 10.6 IDH2 IDH1 FGFR1
36 protoplasmic astrocytoma 10.6 TP53 IDH2
37 undifferentiated pleomorphic sarcoma 10.6 PIK3CA IDH2 IDH1
38 glioma susceptibility 1 10.6 TP53 IDH2 IDH1
39 hyperplastic polyposis syndrome 10.6 TP53 BRAF
40 pilocytic astrocytoma of cerebellum 10.6 IDH2 IDH1 BRAF
41 breast carcinoma in situ 10.6 TP53 FGFR1 EGFR
42 bile duct adenocarcinoma 10.5 TP53 IDH2 IDH1
43 spinal cord astrocytoma 10.5 TP53 IDH1 BSG
44 respiratory system cancer 10.5 TP53 PIK3CA EGFR
45 colorectal adenocarcinoma 10.5 TP53 EGFR BRAF
46 bladder squamous cell carcinoma 10.5 TP53 BRAF
47 uterine carcinosarcoma 10.5 TP53 PIK3CA EGFR
48 recurrent respiratory papillomatosis 10.5 TP53 EGFR
49 ovarian serous cystadenocarcinoma 10.5 TP53 PIK3CA BRAF
50 asbestos-related lung carcinoma 10.5 PDGFB EGFR

Graphical network of the top 20 diseases related to Brain Stem Glioma:



Diseases related to Brain Stem Glioma

Symptoms & Phenotypes for Brain Stem Glioma

GenomeRNAi Phenotypes related to Brain Stem Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.85 ACVR1 PDGFB
2 Decreased substrate adherent cell growth GR00193-A-2 9.85 PDGFB
3 Decreased substrate adherent cell growth GR00193-A-3 9.85 ACVR1 BRAF PDGFB
4 Decreased substrate adherent cell growth GR00193-A-4 9.85 ACVR1 BRAF FGFR1 PDGFB
5 Decreased cell migration GR00055-A-1 9.65 ACVR1 BRAF EGFR PIK3CA PPM1D
6 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR PPM1D
7 Decreased viability with paclitaxel GR00179-A-2 9.35 PPM1D
8 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR PPM1D
9 Increased cell migration GR00055-A-3 9.02 ACVR1 BRAF EGFR PIK3CA PPM1D

MGI Mouse Phenotypes related to Brain Stem Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 ACVR1 BRAF EGFR IDH2 PIK3CA PPM1D

Drugs & Therapeutics for Brain Stem Glioma

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Carmustine For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas. DB00262

Drugs for Brain Stem Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
3
leucovorin Approved Phase 3 58-05-9 143 6006
4
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
8
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
9
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Thioguanine Approved Phase 3 154-42-7 2723601
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Vorinostat Approved, Investigational Phase 2, Phase 3 149647-78-9 5311
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Anti-Inflammatory Agents Phase 3
23 Antirheumatic Agents Phase 3
24 Nucleic Acid Synthesis Inhibitors Phase 3
25 Folic Acid Antagonists Phase 3
26 Folate Phase 3
27 Vitamin B9 Phase 3
28 Vitamin B Complex Phase 3
29 glucocorticoids Phase 3
30 Analgesics Phase 3
31 Peripheral Nervous System Agents Phase 3
32 Antimetabolites Phase 3
33 Antimetabolites, Antineoplastic Phase 3
34 BB 1101 Phase 3
35 Antibodies, Monoclonal Phase 2, Phase 3
36 Liver Extracts Phase 3
37 Central Nervous System Depressants Phase 3
38 Nootropic Agents Phase 3
39 Cholinesterase Inhibitors Phase 3
40 Cholinergic Agents Phase 3
41 Mitogens Phase 2, Phase 3
42 Immunoglobulin G Phase 2, Phase 3
43 Endothelial Growth Factors Phase 2, Phase 3
44 Antiemetics Phase 3
45 Autonomic Agents Phase 3
46 Emetics Phase 3
47 Histone Deacetylase Inhibitors Phase 2, Phase 3
48 Cola Phase 3
49 Anesthetics, Intravenous Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
2 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
4 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
5 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
6 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
8 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02864888 Phase 3 Atengenal;Astugenal
10 A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02887040 Phase 3 Atengenal;Astugenal
11 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
12 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
14 A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas Unknown status NCT00514397 Phase 2 motexafin gadolinium;temozolomide
15 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
16 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Unknown status NCT00879437 Phase 2 Valproic acid;Bevacizumab
17 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
18 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
19 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Stem Glioma Completed NCT00003459 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
20 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
21 Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Completed NCT00179881 Phase 2 Carboplatin;Thalomid
22 Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal Completed NCT00003466 Phase 2 temozolomide
23 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
24 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate
25 A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood Completed NCT00387790 Phase 2 motexafin gadolinium
26 A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas Completed NCT01118377 Phase 2 Capecitabine
27 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
28 Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma Completed NCT01145170 Phase 2
29 Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide Completed NCT00004068 Phase 2 irinotecan hydrochloride;temozolomide
30 A TRIAL OF INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RECONSTITUTION FOR PATIENTS BETWEEN SIX AND SIXTY YEARS OF AGE, WITH NON-PROGRESSIVE GLIOBLASTOMA MULTIFORME OR DIFFUSE INTRINSIC BRAINSTEM TUMORS, FOLLOWING INITIAL LOCAL-FIELD IRRADIATION Completed NCT00002619 Phase 2 carboplatin;thiotepa
31 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
32 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
33 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
34 A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS Completed NCT00002825 Phase 2 docetaxel
35 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
36 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
37 Phase I/II Trial of R115777 and XRT in Pediatric Patients With Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas Completed NCT00079339 Phase 1, Phase 2 tipifarnib
38 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
39 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
40 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
41 A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas Completed NCT00064363 Phase 2 talampanel
42 A Phase II Trial of Irinotecan in Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
43 Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors. Completed NCT00003457 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
44 A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients With Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors Completed NCT00275002 Phase 2 O6-benzylguanine;temozolomide
45 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
46 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
47 Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
48 Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
49 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
50 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride

Search NIH Clinical Center for Brain Stem Glioma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carmustine

Genetic Tests for Brain Stem Glioma

Anatomical Context for Brain Stem Glioma

MalaCards organs/tissues related to Brain Stem Glioma:

41
Brain, Spinal Cord, T Cells, Liver, Bone, Endothelial, Pons

Publications for Brain Stem Glioma

Articles related to Brain Stem Glioma:

(show top 50) (show all 175)
# Title Authors PMID Year
1
(Doctor…My child keeps falling over) unexpected MRI findings in children with history of frequent falls and dizziness: a case series. 38
31272995 2019
2
IDH1 Mutation in Brain Stem Glioma: Case Report and Review of Literature. 38
29682047 2018
3
Spontaneous complete regression of a brain stem glioma pathologically diagnosed as a high-grade glioma. 38
28808781 2017
4
Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. 38
28681244 2017
5
The Role of telovelar approach in fourth ventricular surgery: a new perspective. 38
29044454 2017
6
A Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child. 38
27867930 2016
7
[Brain stem glioma: a rare cause of central vertigo in adults]. 38
28292097 2016
8
Clinical profile and outcomes in brainstem glioma: An institutional experience. 38
26425160 2015
9
Torticollis in children: an alert symptom not to be turned away. 38
26043711 2015
10
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. 38
25930724 2015
11
Comparison of Direct Side-to-End and End-to-End Hypoglossal-Facial Anastomosis for Facial Nerve Repair. 38
25819525 2015
12
Comment to the paper "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma" by Burzynski et al. 38
25142686 2014
13
Clinicopathological features and treatment outcomes of brain stem gliomas in Saudi population. 38
25493242 2014
14
Brain stem glioma with spinal cord involvement in a young with neurofibromatosis type 1. 38
24614250 2014
15
[Blepharospasm as the presenting symptom of a brain stem glioma]. 38
24570363 2014
16
Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. 38
23801675 2013
17
Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation. 38
23053494 2013
18
[Diagnostic value of brain biopsy in a pediatric multiple sclerosis mimicking brain stem glioma]. 38
23812076 2013
19
Paediatric intra-axial posterior fossa tumours: pictorial review. 38
22977284 2013
20
Intracranial syphilitic gumma mimicking a brain stem glioma. 38
22723064 2012
21
Treatment of progressive brain stem glioma with bevacizumab: radiological, metabolic and histopathological aspects. 38
22048887 2012
22
Shall we treat hydrocephalus associated to brain stem glioma in children? 38
21928037 2011
23
Hydrocephalus in patients with neurofibromatosis type 1: MR imaging findings and the outcome of endoscopic third ventriculostomy. 38
21330395 2011
24
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. 38
21233173 2011
25
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. 38
20658614 2010
26
DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. 38
20363335 2010
27
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. 38
20371725 2010
28
Imaging and clinical features of an intra-axial brain stem schwannoma. 38
19833800 2010
29
Diffuse brain stem glioma. 38
20212241 2010
30
[Diffuse intrinsic brain stem glioma in children: current treatment and future directions]. 38
20018494 2010
31
Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. 38
21483304 2009
32
Commentary on diffuse brain stem glioma in children. 38
19016114 2008
33
Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. 38
18324354 2008
34
Diagnostic and therapeutic challenges owing to concurrent pontine glioma and acute lymphoblastic leukemia. 38
18525463 2008
35
Citrate in pediatric CNS tumors? 38
18272551 2008
36
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. 38
17278121 2008
37
Brain stem glioma, a rare cause of hearing loss and dysequilibrium. 38
21063295 2008
38
HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature. 38
17593375 2007
39
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 38
17705175 2007
40
Somatostatin-receptor positive brain stem glioma visualized by octreoscan. 38
17627256 2007
41
Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail. 38
17492930 2007
42
Establishment of experimental glioma models at the intrinsic brainstem region of the rats. 38
17427273 2007
43
Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation. 38
16847598 2006
44
Primary midbrain cystic germinoma mimicking glioma: a case with neuroendoscopic biopsy. 38
16557347 2006
45
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. 38
16047359 2006
46
Temozolomide in resistant or relapsed pediatric solid tumors. 38
16047361 2006
47
Quality of health information on the Internet in pediatric neuro-oncology. 38
16533758 2006
48
ACTH deficiency in childhood cancer survivors. 38
15700255 2005
49
Hemifacial spasm caused by pontine glioma: case report and review of the literature. 38
16001287 2005
50
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. 38
16136028 2005

Variations for Brain Stem Glioma

ClinVar genetic disease variations for Brain Stem Glioma:

6 (show top 50) (show all 80)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PIK3CA NM_006218.4(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 3:178938934-178938934 3:179221146-179221146
2 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
7 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
8 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
9 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
10 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
11 ACVR1 NM_001105.5(ACVR1): c.983G> A (p.Gly328Glu) single nucleotide variant Pathogenic rs387906589 2:158622516-158622516 2:157766004-157766004
12 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
13 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
14 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
15 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 8:38274849-38274849 8:38417331-38417331
16 TP53 NM_000546.5(TP53): c.517G> A (p.Val173Met) single nucleotide variant Pathogenic/Likely pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
17 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
18 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
19 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
20 IDH1 NM_005896.3(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
21 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
22 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
23 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 17:7577538-7577538 17:7674220-7674220
24 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 17:7578407-7578407 17:7675089-7675089
25 TP53 NM_000546.5(TP53): c.817C> A (p.Arg273Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913343 17:7577121-7577121 17:7673803-7673803
26 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
27 IDH1 NM_005896.3(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
28 IDH1 NM_005896.3(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
29 IDH1 NM_005896.3(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
30 PIK3CA NM_006218.4(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 3:178936091-178936091 3:179218303-179218303
31 IDH2 NM_002168.3(IDH2): c.515G> T (p.Arg172Met) single nucleotide variant Pathogenic/Likely pathogenic rs121913503 15:90631838-90631838 15:90088606-90088606
32 IDH2 NM_002168.3(IDH2): c.515G> A (p.Arg172Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913503 15:90631838-90631838 15:90088606-90088606
33 TP53 NM_000546.5(TP53): c.518T> C (p.Val173Ala) single nucleotide variant Likely pathogenic rs1057519747 17:7578412-7578412 17:7675094-7675094
34 PIK3CA NM_006218.4(PIK3CA): c.263G> A (p.Arg88Gln) single nucleotide variant Likely pathogenic rs121913287 3:178916876-178916876 3:179199088-179199088
35 EGFR NM_005228.5(EGFR): c.1793G> T (p.Gly598Val) single nucleotide variant Likely pathogenic rs139236063 7:55233043-55233043 7:55165350-55165350
36 ACVR1 NM_001105.5(ACVR1): c.983G> T (p.Gly328Val) single nucleotide variant Likely pathogenic rs387906589 2:158622516-158622516 2:157766004-157766004
37 ACVR1 NM_001105.5(ACVR1): c.773G> T (p.Arg258Met) single nucleotide variant Likely pathogenic rs1057519875 2:158626897-158626897 2:157770385-157770385
38 EGFR NM_005228.5(EGFR): c.1793G> C (p.Gly598Ala) single nucleotide variant Likely pathogenic rs139236063 7:55233043-55233043 7:55165350-55165350
39 EGFR NM_005228.5(EGFR): c.322A> G (p.Arg108Gly) single nucleotide variant Likely pathogenic rs1057519888 7:55211079-55211079 7:55143386-55143386
40 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 8:38274851-38274851 8:38417333-38417333
41 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 8:38275397-38275397 8:38417879-38417879
42 H3-3A NM_002107.6(H3-3A): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs1057519902 1:226252152-226252152 1:226064451-226064451
43 H3-3A NM_002107.6(H3-3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 1:226252135-226252135 1:226064434-226064434
44 H3C11 NM_003533.2(H3C11): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519904 6:27840011-27840011 6:27872233-27872233
45 H3C11 NM_003533.2(H3C11): c.82A> G (p.Lys28Glu) single nucleotide variant Likely pathogenic rs1057519905 6:27840012-27840012 6:27872234-27872234
46 IDH2 NM_002168.3(IDH2): c.514A> T (p.Arg172Trp) single nucleotide variant Likely pathogenic rs1057519906 15:90631839-90631839 15:90088607-90088607
47 IDH2 NM_002168.3(IDH2): c.514A> G (p.Arg172Gly) single nucleotide variant Likely pathogenic rs1057519906 15:90631839-90631839 15:90088607-90088607
48 TP53 NM_000546.5(TP53): c.722C> A (p.Ser241Tyr) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
49 TP53 NM_000546.5(TP53): c.721T> C (p.Ser241Pro) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
50 TP53 NM_000546.5(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242

Expression for Brain Stem Glioma

Search GEO for disease gene expression data for Brain Stem Glioma.

Pathways for Brain Stem Glioma

Pathways related to Brain Stem Glioma according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 TP53 PIK3CA PDGFB FGFR1 EGFR BRAF
2 12.68 TP53 PIK3CA PDGFB FGFR1 EGFR BRAF
3 12.66 TP53 PDGFB FGFR1 EGFR BRAF
4
Show member pathways
12.66 TP53 PIK3CA FGFR1 EGFR BRAF
5
Show member pathways
12.63 PIK3CA PDGFB FGFR1 EGFR BRAF
6
Show member pathways
12.61 TP53 PIK3CA PDGFB FGFR1 EGFR
7 12.52 PIK3CA PDGFB FGFR1 EGFR BRAF
8 12.43 TP53 PIK3CA PDGFB EGFR
9
Show member pathways
12.41 TP53 PIK3CA PDGFB EGFR BRAF
10
Show member pathways
12.37 TP53 PIK3CA FGFR1 EGFR BRAF
11
Show member pathways
12.33 TP53 PIK3CA PDGFB FGFR1 EGFR BRAF
12
Show member pathways
12.31 PIK3CA PDGFB FGFR1 EGFR BRAF
13
Show member pathways
12.19 TP53 PIK3CA FGFR1 EGFR ACVR1
14
Show member pathways
12.06 TP53 PIK3CA BRAF ACVR1
15 12.02 TP53 PIK3CA FGFR1 EGFR
16
Show member pathways
11.99 TP53 PIK3CA FGFR1 EGFR BRAF
17 11.98 TP53 PIK3CA PDGFB ACVR1
18
Show member pathways
11.89 TP53 PIK3CA EGFR BRAF
19 11.86 TP53 PIK3CA FGFR1 EGFR BRAF
20 11.84 FGFR1 EGFR BRAF
21 11.82 PIK3CA EGFR BRAF
22 11.78 TP53 PDGFB EGFR BRAF
23
Show member pathways
11.71 PIK3CA FGFR1 BRAF
24 11.64 PDGFB FGFR1 EGFR BRAF
25 11.64 TP53 EGFR BRAF
26 11.3 PIK3CA FGFR1 EGFR BRAF
27 10.93 PIK3CA EGFR BRAF
28 10.89 PDGFB FGFR1 EGFR BRAF
29 10.86 TP53 PIK3CA IDH1 FGFR1 EGFR
30
Show member pathways
10.74 IDH2 IDH1

GO Terms for Brain Stem Glioma

Biological processes related to Brain Stem Glioma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.8 PDGFB FGFR1 EGFR BRAF
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.72 PIK3CA EGFR BRAF
3 liver development GO:0001889 9.71 UGT1A1 PIK3CA EGFR
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.7 PDGFB EGFR BRAF
5 peptidyl-tyrosine phosphorylation GO:0018108 9.67 PDGFB FGFR1 EGFR BRAF
6 positive regulation of protein kinase B signaling GO:0051897 9.62 PIK3CA PDGFB FGFR1 EGFR
7 cellular response to drug GO:0035690 9.61 TP53 EGFR BRAF
8 positive regulation of MAP kinase activity GO:0043406 9.58 PDGFB FGFR1 EGFR
9 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.56 TP53 PPM1D
10 salivary gland morphogenesis GO:0007435 9.51 FGFR1 EGFR
11 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 TP53 EGFR
12 NADP metabolic process GO:0006739 9.46 IDH2 IDH1
13 isocitrate metabolic process GO:0006102 9.26 IDH2 IDH1
14 protein phosphorylation GO:0006468 9.17 PPM1D PIK3CA PDGFB FGFR1 EGFR BRAF
15 glyoxylate cycle GO:0006097 8.96 IDH2 IDH1
16 phosphatidylinositol phosphorylation GO:0046854 8.85 PIK3CA

Molecular functions related to Brain Stem Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.72 UGT1A1 TP53 PDGFB EGFR BRAF
2 protein homodimerization activity GO:0042803 9.65 UGT1A1 PDGFB IDH1 FGFR1 ACVR1
3 isocitrate dehydrogenase activity GO:0004448 9.16 IDH2 IDH1
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.32 PIK3CA

Sources for Brain Stem Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....